Breast cancer treatment now depends heavily on tumour biology, and immunotherapy has become a key option for certain subtypes. This article explains how breast cancer is diagnosed and staged in Germany, the standard treatment options, and how immunotherapy works through checkpoint inhibitors and dendritic cell therapy. It covers who benefits by subtype, how immunotherapy compares with chemotherapy, side effects and their management, survival by stage, treatment costs, leading centres and how international patients arrange a specialist second opinion.

Immunotherapy for Breast Cancer in Germany

Breast cancer treatment has changed significantly in recent years as advances in tumour biology have made personalised care possible. Immunotherapy for breast cancer is one of the most important developments, helping the immune system recognise and attack cancer cells in selected patients particularly in certain high-risk or advanced triple-negative breast cancers, where immune-checkpoint inhibitors such as pembrolizumab may be used in defined clinical settings [1]. 

Patients travelling to Germany can access comprehensive breast cancer care, where multidisciplinary teams coordinate diagnosis, treatment planning and follow-up according to each patient's needs. TIG GmbH helps international patients arrange specialist consultations, treatment coordination and related logistical arrangements with German cancer with leading cancer centres across Germany.

Breast Cancer and its Types

Breast cancer develops when abnormal cells in the breast begin growing uncontrollably, forming a tumour that most commonly starts in the milk ducts or lobules. In many patients, the disease is invasive, meaning it has spread beyond its original location into the surrounding breast tissue [1].

Common Types of Breast Cancer

Breast cancer is classified into four main molecular subtypes according to receptor status, HER2 status and other pathological and molecular characteristics; commonly described groups include luminal A, luminal B, HER2-positive and triple-negative breast cancer. Identifying the correct subtype is an important part of breast cancer diagnosis because each responds differently to available breast cancer treatments [1].

• Luminal A and luminal B: hormone receptor-positive tumours that usually respond to hormone therapy.
• HER2-enriched: tumours that overexpress HER2 and respond to HER2-targeted drugs.
• Triple-negative (TNBC): lacks all three receptors, makes up roughly 15% to 20% of cases, and tends to affect younger women. TNBC accounts for a substantial minority of breast cancers and is more common in younger women and in certain populations, although it can occur at any age.

Why Breast Cancer Treatment Is Personalized

Modern breast cancer treatment is tailored to each patient because the tumour's biological features help determine which therapies are most likely to be effective. Two tumours of the same size can require completely different treatments if they belong to different molecular subtypes [1].

One study found that luminal B, HER2-positive and triple-negative tumours responded better to neoadjuvant chemotherapy than luminal A tumours. These findings support the use of personalized breast cancer treatment in Germany based on each patient's tumour characteristics [10].

Breast Cancer Diagnosis and Staging in Germany

Every breast cancer treatment plan begins with an accurate diagnosis and a clear understanding of the tumour's characteristics. In Germany, imaging, biopsy and molecular testing are used to confirm the diagnosis and characterise the tumour biomarker testing, including ER, PR and HER2 assessment, helps guide treatment selection.

Diagnostic Tests Required Before Breast Cancer Immunotherapy 

Breast cancer diagnosis usually begins with imaging tests such as mammography and ultrasound, which help identify and evaluate suspicious areas in the breast. MRI may also be recommended when additional information is needed to assess the extent of the disease [2].

Although imaging can indicate whether an abnormality is suspicious, it cannot confirm cancer on its own. A biopsy is therefore required to establish the diagnosis and distinguish cancer from benign conditions while helping avoid unnecessary procedures.

Biopsy and Biomarker Testing

During a biopsy, a small tissue sample is collected so that a pathologist can confirm cancer and identify its molecular subtype. The sample is also tested for important biomarkers, including the oestrogen receptor, progesterone receptor and HER2, which play a central role in breast cancer diagnosis and treatment planning [1].

These results help clinicians determine which treatments are appropriate and whether hormone therapy or HER2-directed therapy, among other options, should be considered. For those being considered for immunotherapy, additional testing, includin, is often needed to confirm eligibility [5].

Breast Cancer Staging

Staging describes how far the cancer has spread, from stage 0 confined to the ducts through to stage 4 with distant metastasis. Stage combines with subtype to determine breast cancer treatment by stage [1].

Breast Cancer Treatment Options in Germany

The treatment for breast cancerin Germany combines local and systemic approaches, tailored to subtype and stage. Several treatments are usually used together rather than in isolation.

Surgery in Breast Cancer Treatment 

Surgery remains one of the main breast cancer treatment options for patients with early and locally advanced disease although the timing and role of surgery depend on tumour subtype, stage, operability and the planned systemic treatment. Depending on the tumour size, its location, and the patient's preferences, doctors may recommend either breast-conserving surgery or a mastectomy. Surgery aims to remove the tumour completely, but many patients also receive chemotherapy, radiation therapy or hormone therapy to lower the risk of the cancer returning and additional systemic therapy and/or radiation therapy may be recommended according to the tumour subtype, stage, pathological findings and estimated risk of recurrence [1]. 

Chemotherapy for Breast Cancer 

Chemotherapy for breast cancer uses drugs that destroy rapidly dividing cancer cells, given before surgery to shrink a tumour or after surgery to reduce recurrence. Triple-negative tumours respond particularly well to neoadjuvant breast cancer chemotherapy and neoadjuvant systemic therapy is an important component of treatment for many patients with high-risk early-stage disease [10]. Chemotherapy also affects healthy dividing cells, so side effects such as hair loss and low blood counts are common. For this reason, more targeted breast cancer drugs have become an important part of treatment.

Radiation Therapy in Breast Cancer Treatment 

Radiation treatment for breast cancer targets cancer cells that may remain after surgery, lowering the risk of local recurrence. It is standard after breast-conserving surgery and in selected higher-risk cases after mastectomy. Because radiation only treats the affected area, it is usually combined with other treatments that work throughout the body. For many patients, it is an important part of a multimodal treatment plan [1].

Hormone Therapy for Hormone Receptor-Positive Breast Cancer 

Hormone therapy benefits patients with hormone receptor-positive tumours, which rely on oestrogen to grow. Drugs such as tamoxifen and aromatase inhibitors block this signal over several years. Treatment usually continues for several years to reduce the risk of recurrence in hormone receptor-positive breast cancer [1].

Targeted Therapy for HER2-Positive Breast Cancer 

Targeted therapy is used when a tumour carries a specific molecular feature that a drug can attack. For HER2-positive disease, drugs such as trastuzumab bind the HER2 receptor and have transformed outcomes for that subtype [1]. Since these medicines focus on specific cancer targets, they usually affect healthy tissues less than traditional chemotherapy.

How Immunotherapy Treats Breast Cancer in Germany

Breast cancer immunotherapy uses the immune system to recognise and attack cancer cells. It is now an established treatment option for selected patients, particularly those with triple-negative breast cancer.

How Does Immunotherapy Work?

Cancer cells often evade the immune system by switching off the T cells that would otherwise attack them. Immunotherapy restores or creates that immune response, allowing the body to target the tumour [5]. Depending on the treatment, immunotherapy either removes the signals that stop immune cells from attacking cancer or trains them to recognise tumour cells more effectively. Both approaches aim to produce a lasting anti-tumour response.

Types of Breast Cancer Immunotherapy

Two main forms are currently used or studied in breast cancer, checkpoint inhibitors and cellular therapies such as dendritic cell vaccines. They differ in how they work and in the level of clinical evidence supporting them

Checkpoint Inhibitors for Breast Cancer

Checkpoint inhibitors block proteins like PD-1 and PD-L1 that cancer uses to switch off immune cells. Releasing this brake lets T cells attack the tumour, and pembrolizumab is the leading example in breast cancer.

In the KEYNOTE-522 trial, adding pembrolizumab to chemotherapy raised the pathologic complete response rate from 51.2% to 64.8% in stage II and III triple-negative disease. This regimen has become standard of care for early triple-negative breast cancer [5] [7].

Dendritic Cell Therapy for Breast cancer in Germany

Dendritic cell therapy for breast cancer in Germany is a personalised, cell-based immunotherapy that trains a patient’s own immune cells to recognise their tumour. The treatment begins by collecting immune cells from the patient's blood. These cells are developed into dendritic cells in a specialised laboratory, exposed to tumour antigens and then administered back to stimulate an immune response.

In a phase I trial of a HER2-directed dendritic cell vaccine, this approach induced new anti-HER2 immune responses in 10 of 11 evaluable patients, with 7 of 21 (33.3%) showing a clinical benefit [4]. 

Approved Immunotherapy Drugs in Germany

In Germany, checkpoint inhibitors such as pembrolizumab are approved and used within guideline-based breast cancer treatment in Germany, chiefly for triple-negative disease. Personalised cellular therapies, including dendritic cell vaccines, may be available under the European ATMP framework and the German Medicines Act (AMG), although they are not considered first-line standard treatment [4] [5] [7].

Who Can Benefit from Breast Cancer Immunotherapy?

Immunotherapy is not suitable for every patient, and eligibility depends on subtype, stage and biomarker status. 

Immunotherapy for Early-Stage Breast Cancer 

Patients with early, high-risk triple-negative disease are among the clearest candidates for immunotherapy. In this setting, adding pembrolizumab to chemotherapy improved event-free survival from 76.8% to 84.5% [7]. These benefits have been demonstrated mainly in patients with stage II and III triple-negative breast cancer.

Immunotherapy for Triple-Negative Breast Cancer (TNBC)

Triple-negative breast cancer benefits most from immunotherapy, partly because it tends to provoke a stronger immune response than other subtypes. It also has fewer targeted options, so immunotherapy fills a genuine gap. Checkpoint inhibitors are now standard in high-risk early TNBC and used in selected metastatic cases [3] [5] [7]. 

Immunotherapy for HER2-Positive Breast Cancer

HER2-positive disease is primarily treated with HER2-targeted drugs, but it is also the focus of dendritic cell vaccine research. HER2 provides a clear target antigen for a personalised vaccine. In the HER2-directed dendritic cell trial, patients treated in an adjuvant setting after standard therapy showed encouraging early signals, though the numbers were small [4]. 

Immunotherapy for Metastatic Breast Cancer

For advanced disease, immunotherapy for metastatic breast cancer is used in selected PD-L1-positive triple-negative cases, based on trial evidence. It is combined with chemotherapy rather than used alone. Cellular therapies are also being studied in this setting as a complementary option. For eligible patients with metastatic triple-negative breast cancer, immunotherapy has created treatment opportunities that were not previously available [4] [5].

Immunotherapy vs Chemotherapy for Breast Cancer

Immunotherapy and chemotherapy work in fundamentally different ways, and in breast cancer they are often used together rather than as alternatives. 

Differences between Immunotherapy and Chemotherapy

Chemotherapy directly kills rapidly dividing cells, including healthy ones, which drives its side effects. Immunotherapy instead activates the immune system to target cancer, which can produce more durable responses in some patients. Their timelines differ too. Chemotherapy acts quickly, while immunotherapy may take longer to show its full effect as the immune response builds [5].

Combination Treatment with Immunotherapy and Chemotherapy 

Combination treatment is recommended in high-risk triple-negative disease, where chemotherapy and a checkpoint inhibitor together outperform chemotherapy alone. Chemotherapy can make cancer cells easier for the immune system to recognise, which is one reason these treatments are often used together [5] [7].

Benefits and Limitations of Immunotherapy and Chemotherapy 

Chemotherapy works across many subtypes and acts fast, but its side effects can be significant and its benefit is not always durable. Immunotherapy can produce lasting responses and is better tolerated in some respects, though it helps a narrower group and carries its own immune-related risks [8].

Risks and Side Effects of Breast Cancer Immunotherapy

Immunotherapy is generally well tolerated, but it carries a distinct pattern of side effects driven by an activated immune system. 

Common Side Effects 

Common adverse effects of immune checkpoint inhibitors include fatigue, rash, diarrhea, and immune-mediated endocrine disorders such as thyroid dysfunction; and less commonly, other endocrine organs can also be affected. With dendritic cell therapy, the main effect is a mild injection-site reaction, seen in 94% of patients in one trial and resolving within four to five days. Early recognition and appropriate management of treatment-related adverse effects can reduce complications and, when clinically appropriate, mostly allows immunotherapy to be continued or resumed [4].

Immune-Related Side Effects of Immunotherapy 

Checkpoint inhibitors can occasionally cause the immune system to attack healthy organs, producing immune-related adverse events such as colitis, hepatitis or pneumonitis. In one triple-negative cohort, most patients who stopped pembrolizumab early did so because of these events. These reactions can be serious but are usually reversible when caught early. Cellular therapies like dendritic cell vaccines have shown a lower rate of severe immune reactions [4] [8].

Management of Immunotherapy Side Effects 

Immune-related side effects are managed with close monitoring and, when needed, medication to calm the immune response. German centres build this monitoring into the treatment schedule, with regular clinical review and blood tests. Supportive care allows most patients to continue treatment safely.

Breast Cancer Prognosis and Survival 

The breast cancer prognosis depends heavily on the stage at diagnosis, the subtype and how well the tumour responds to treatment. Treatment outcomes have improved considerably over the past two decades as breast cancer therapies have become more precise [1].

Factors That Influence Treatment Outcomes

Stage at diagnosis is the strongest single factor, with earlier disease carrying a far better outlook [8]. Subtype, tumour grade and response to initial treatment also shape the result. For some breast cancer subtypes, particularly triple-negative breast cancer, achieving a pathological complete response after neoadjuvant therapy is associated with a more favorable prognosis [5].

Breast Cancer Survival Rates by Stage

Survival figures are population averages and cannot predict any individual outcome, but they show clearly why early detection matters. The chart below presents reported 5-year survival by extent of spread.

For localised breast cancer, the reported 5-year survival is 99%, falling to 86% for regional disease and 27% for distant metastatic disease. In a separate registry cohort, breast cancer-specific survival ranged from 97% in stage I to 32% in stage IV [8] [9].

Can Breast Cancer Be Cured?

The question of whether breast cancer is curable depends on the stage and subtype. The breast cancer cure rate is highest when the disease is diagnosed early, which is reflected in the high survival for localised tumours. Although metastatic breast cancer is usually managed as a long-term condition rather than cured, modern treatments can help many patients live longer while maintaining a good quality of life. For breast cancer stage 4 treatment, the goal is durable control and quality of life [8] [9].

Why Choose Germany for Breast Cancer Immunotherapy?

Germany has become a recognised destination for breast cancer treatment because patients can access experienced specialists, advanced diagnostics and innovative therapies within a highly regulated healthcare system. This makes immunotherapy for breast cancer in Germany available alongside guideline-based standard care while investigational approaches such as dendritic-cell vaccines may be available only through appropriate clinical trials or specialized programs.

Breast Cancer Specialists and Cancer Centres in Germany 

German university hospitals and comprehensive cancer centres are known for high patient volumes and integrated care. A breast cancer specialist in Germany or breast cancer oncologist in Germany typically reviews each case within a multidisciplinary tumour board.These breast cancer treatment hospitals in Germany bring together surgery, oncology, radiation and pathology under one roof. 

Precision Medicine and Molecular Diagnostics

Precision medicine combines molecular profiling with clinical findings to help doctors choose the most appropriate treatment strategy. Biomarker testing, including PD-L1 assessment, also helps identify patients who are most likely to benefit from immunotherapy [5]. 

Multidisciplinary Treatment Planning

Each patient's case is reviewed by surgeons, medical oncologists, radiation specialists and pathologists to develop a coordinated treatment plan. This reduces the risk of fragmented care and delays.For international patients seeking advanced breast cancer treatment in Germany, this coordinated model is a key advantage. It keeps complex, multi-step treatment on track.

Access to Clinical Trials and Innovative Therapies

Many German cancer centres participate in international clinical trials, allowing eligible patients to access promising new therapies when standard treatment options are limited. Specialist centres may also offer innovative cellular therapies, including dendritic cell vaccines [4] [5]

How Much Does Breast Cancer Immunotherapy Cost in Germany?

The breast cancer treatment cost in Germany depends on the diagnosis, the therapies chosen and the length of care, so every patient receives an individual estimate after their records are reviewed. Some therapies carry a defined indicative price. The overall treatment cost depends on the type of immunotherapy recommended, the number of treatment cycles and the patient's individual treatment plan. A complete course of dendritic cell therapy costs approximately twenty-seven thousand euros and is provided by Prof. Gansauge at LDG Laboratories, who specialises in personalised dendritic cell immunotherapy and cellular cancer treatments. 

Checkpoint inhibitor therapy is priced separately and depends on the number of cycles given. Standard treatments such as surgery, chemotherapy and radiation are quoted individually.

What Influences the Overall Cost?

Several factors influence the total. These include whether immunotherapy is combined with other treatments, the number of drug cycles, the length of hospital stay, and the amount of diagnostic testing and follow-up required.

Insurance and Payment Considerations

Coverage depends on each patient’s insurance and country of origin, and investigational cellular therapies are often not reimbursed. Receiving a written treatment estimate before travelling helps patients understand the expected costs and plan accordingly.

Support for International Patients

International patients usually begin the process by submitting their medical records for specialist review before any travel arrangements are made. 

Medical Report Review and Second Opinion

Existing pathology, imaging and treatment records are reviewed by a German specialist before any travel is arranged. A breast cancer second opinion in Germany is provided as a written report, confirming whether the proposed plan follows current guidelines.

Personalized Breast Cancer Treatment Planning

Following review, a specialist prepares an individualised plan based on the tumour subtype, stage and biomarker status. This approach allows treatment to be tailored to the patient's individual diagnosis instead of following a standard treatment pathway.

Visa and Travel Support

Patients receive support with medical visa documentation and travel planning to help ensure a smooth treatment journey. 

Medical Interpreter and Follow-Up Support 

Medical interpreters assist with consultations, consent discussions and discharge instructions. Follow-up services, including remote review of imaging, continue after the patient returns home.

International patients usually follow this pathway: medical records, then specialist review, then a treatment plan, then travel, then treatment, and finally follow-up. 

Why Choose TIG for Breast Cancer Treatment in Germany?

TIG GmbH coordinates the full pathway for international patients, from the first report review through to follow-up after they return home. The team coordinates the administrative and logistical aspects of treatment, allowing patients and their families to focus on medical care.

Request a Personalised Breast Cancer Treatment Review 

Send your pathology report, recent imaging and treatment history for a specialist review by a German breast oncologist through TIG GmbH. Ask directly whether your tumour subtype and biomarker status make you a candidate for immunotherapy, how it would combine with standard treatment, and what a realistic plan and timeline would involve. 

References

1. Smolarz, B., Nowak, A. Z., & Romanowicz, H. (2022). Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers, 14(10), 2569. 

2. Szep, M., Pintican, R., Boca, B., Perja, A., Duma, M., Feier, D., Fetica, B., Eniu, D., Dudea, S. M., & Chiorean, A. (2022). Multiparametric MRI Features of Breast Cancer Molecular Subtypes. Medicina (Kaunas, Lithuania), 58(12), 1716. 

3. Zajac, K. K., Malla, S., Babu, R. J., Raman, D., & Tiwari, A. K. (2023). Ethnic disparities in the immune microenvironment of triple negative breast cancer and its role in therapeutic outcomes. Cancer reports (Hoboken, N.J.), 6 Suppl 1(Suppl 1), e1779. 

4. Maeng, H. M., Moore, B. N., Bagheri, H., Steinberg, S. M., Inglefield, J., Dunham, K., Wei, W. Z., Morris, J. C., Terabe, M., England, L. C., Roberson, B., Rosing, D., Sachdev, V., Pack, S. D., Miettinen, M. M., Barr, F. G., Weiner, L. M., Panch, S., Stroncek, D. F., Wood, L. V., … Berzofsky, J. A. (2021). Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy. Frontiers in oncology, 11, 789078. 

5.  Nederlof, I., Voorwerk, L., & Kok, M. (2023). Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(13), 2362–2370. 

6.Connors, C., Valente, S. A., ElSherif, A., Escobar, P., Chichura, A., Kopicky, L., Roesch, E., Ritner, J., McIntire, P., Wu, Y., Tu, C., & Lang, J. E. (2025). Real-World Outcomes with the KEYNOTE-522 Regimen in Early-Stage Triple-Negative Breast Cancer. Annals of surgical oncology, 32(2), 912–921. 

7. Marhold, M., Udovica, S., Halstead, A., Hirdler, M., Ferner, M., Wimmer, K., Bago-Horvath, Z., Exner, R., Fitzal, F., Strasser-Weippl, K., Robinson, T., & Bartsch, R. (2023). Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer. Oncoimmunology, 12(1), 2275846. 

8. LeBlanc, G., Lee, I., Carretta, H., Luo, Y., Sinha, D., & Rust, G. (2022). Rural-Urban Differences in Breast Cancer Stage at Diagnosis. Women's health reports (New Rochelle, N.Y.), 3(1), 207–214. 

9. Pessanha, R. M., Grippa, W. R., Neto, L. C. B. S., D'Agostini, N. S., & Lopes-Júnior, L. C. (2026). Breast Cancer-Specific Survival and Prognostic Factors in a Statewide Oncology Network in Brazil: A Registry-Linked Retrospective Cohort Study. Cancer reports (Hoboken, N.J.), 9(2), e70467. 

10. Hashmi, A. A., Bukhari, U., Najam, J., Dowlah, T., Ali, A. H., Diwan, M. A., Anjali, F., Sham, S., Zia, S., & Irfan, M. (2023). Luminal B, Human Epidermal Growth Factor Receptor 2 (HER2/neu), and Triple-Negative Breast Cancers Associated With a Better Chemotherapy Response Than Luminal A Breast Cancers in Postneoadjuvant Settings. Cureus, 15(6), e40066.

Why Patients Worldwide Prefer Our Medical Services in Germany – Key Benefits Explained